Additional file 1: of Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5
presentationposted on 21.06.2016 by Jason Eng, Thomas Mace, Rohit Sharma, Danielle Twum, Peng Peng, John Gibbs, Rosemarie Pitoniak, Chelsey Reed, Scott Abrams, Elizabeth Repasky, Bonnie Hylander
Academic presentations can be uploaded in their original slide format. Presentations are usually represented as slide decks. Videos of presentations can be uploaded as media.
Figure S1. Treatment three times per week of 12424 did not inhibit tumor growth. 12424 tumors implanted SQ into mice and given 200 μg of drozitumab 3×/week. n = 8 mice/group. Figure S2. Tumors derived from purified CSCs recapitulate the morphology of the original patient xenograft. H&E images of the patient pancreatic adenocarcinoma xenograft 14244(A) and the tumor derived from CSCs isolated from that tumor (B). Figure S3. In vitro treatment of tumor cells with drozitumab depletes cancer stem cells. A) Panc-1 pancreatic tumor cells or dissociated tumor cells from B) 12424 were treated in vitro with 10 μg/ml of drozitumab and 10 μg/ml of anti-human IgG Fc antibody for 12 h to ensure maximum killing. The percentages of CSCs were assessed by flow cytometry using markers for ESA, CD44, and CD24. (PPT 664 kb)